CyFlow CD25 Biotin
| 品番 | AT267296 | ||
|---|---|---|---|
| 抗体名 | Anti-Hu CD25 BIOTIN,MEM-181 | ||
| 包装単位 | 0.1 mg | ||
| 濃度 | 1 mg/ml | ||
| 容量 | 0.1 ml | ||
| 関連製品 (アイソタイプコントロール) |
Mouse IgG1 Biotin (AQ807476) |
||
| 反応性|交差吸着 | Human | レーザー | |
| 抗原 | CD25, TAC, p55, IL-2R | 最大蛍光波長 | - |
| クローン | MEM-181 | 最大励起波長 | - |
| ホスト | Mouse | 標識/Format | Biotin |
| アイソタイプ | IgG1 | 研究分野 | Immunophenotyping |
| クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Hu CD25 BIOTIN,MEM-181
特異性
The mouse monoclonal antibody MEM-181 recognizes CD25 antigen, a 55 kDa type I transmembrane glycoprotein expressed on activated B and T lymphocytes, activated monocytes/macrophages and on CD4+ T lymphocytes (T regulatory cells); it is lost on resting B and T lymphocytes.
抗原情報
CD25 (IL2Rα, Tac) is a ligand-binding α subunit of interleukin 2 receptor (IL2R). Together with β and γ subunit CD25 constitues the high affinity IL2R, whereas CD25 alone serves as the low affinity IL2R. CD25 expression rapidly increases upon T cell activation. The 55 kDa CD25 molecule is enzymatically cleaved and shed from the cell surface as a soluble 45 kDa s-Tac, whose concentration in serum can be used as a marker of T cell activation. Expression of CD25 indicates the neoplastic phenotype of mast cells. Humanized anti CD25 antibodies represent a useful tool to reduce the incidence of allograft rejection as well as the severity of graft versus host reaction, and radioimmunoconjugates of anti-CD25 antibodies can be used against CD25 expressing lymphomas.
利用方法
The reagent is designed for indirect immunofluorescence analysis by Flow Cytometry. Suggested working usage is 2 µg/ml. Indicated dilution is recommended starting point for use of this product, but working concentrations should be validated by the investigator.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Drbal K, Moertelmaier M, Holzhauser C, Muhammad A, Fuertbauer E, Howorka S, Hinterberger M, Stockinger H, Schütz GJ: Single‑molecule microscopy reveals heterogeneous dynamics of lipid raft components upon TCR engagement. Int·Immunol. 2007·May; 19(5):675‑84. <·PMID:·17446208·>
• Lai KN, Leung JC, Lai FM: Soluble interleukin 2 receptor release, interleukin 2 production, and interleukin 2 receptor expression in activated T‑lymphocytes in vitro. Pathology. 1991·Jul; 23(3):224‑8. <·PMID:·1838146·>
• Morris JC, Waldmann TA: Advances in interleukin 2 receptor targeted treatment. Ann·Rheum·Dis. 2000·Nov; 59(Suppl 1):i109‑14. <·PMID:·11053100·>
• Scheibenbogen C, Keilholz U, Richter M, Andreesen R, Hunstein W: The interleukin‑2 receptor in human monocytes and macrophages: regulation of expression and release of the alpha and beta chains (p55 and p75). Res·Immunol. 1992·Jan; 143(1):33‑7. <·PMID:·1565844·>
• Sotlar K, Horny HP, Simonitsch I, Krokowski M, Aichberger KJ, Mayerhofer M, Printz D, Fritsch G, Valent P: CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am·J·Surg·Pathol. 2004·Oct; 28(10):1319‑25. <·PMID:·15371947·>
• Kishimoto T, Goyert S, Kikutani H, Mason D, Miyasaka M, Moretta L, Ohno T, Okumura K, Shaw S, Springer TA, Sugamura K, Sugawara H, von dem Borne AEGK, Zola H (Eds): Leucocyte Typing VI. Garland·Publishing·Inc,·New·York. 1997; 1‑1342. <·NLM·ID:·9712219·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN